

## Electronic Acknowledgement Receipt

<b>EFS ID:</b>	1231168
<b>Application Number:</b>	10630587
<b>Confirmation Number:</b>	1664
<b>Title of Invention:</b>	Neuralgia pain treatment by peripheral administration of a neurotoxin
<b>First Named Inventor:</b>	Kei Roger Aoki
<b>Correspondence Address:</b>	Stephen Donovan Allergan, Inc. 2525 Dupont Drive - Irvine CA 92612 US 7142464249 -
<b>Filer:</b>	Claude L. Nassif/Adriane Giberson
<b>Filer Authorized By:</b>	Claude L. Nassif
<b>Attorney Docket Number:</b>	17328CON5
<b>Receipt Date:</b>	02-OCT-2006
<b>Filing Date:</b>	29-JUL-2003
<b>Time Stamp:</b>	17:04:23
<b>Application Type:</b>	Utility
<b>International Application Number:</b>	

### Payment information:

Submitted with Payment	yes
Payment was successfully received in RAM	\$ 1810

RAM confirmation Number	402
Deposit Account	010885
The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows: Charge any Additional Fees required under 37 C.F.R. Section 1.16 and 1.17	

### File Listing:

Document Number	Document Description	File Name	File Size(Bytes)	Multi Part	Pages
1	Transmittal letter	17328CON5Trans.pdf	64877	no	1
Warnings:					
Information:					
2	Extension of Time	17328CON5ExtOfTime.pdf	58505	no	1
Warnings:					
Information:					
3	Request for Continued Examination (RCE)	17328CON5RCETrans.pdf	80648	no	1
Warnings:					
Information:					
4		17328CON5RespFOA041006.pdf	99165	yes	8
	Multipart Description				
	Doc Desc		Start	End	
	Amendment After Final		1	1	
	Applicant Arguments/Remarks Made in an Amendment		2	6	
	Claims		7	8	
Warnings:					
Information:					
5	Oath or Declaration filed	17328CON5POA.pdf	67866	no	1
Warnings:					
Information:					
6	Assignee showing of ownership per 37 CFR 3.73(b).	17328CON5Stmt37CFR373b.pdf	63760	no	1
Warnings:					

<b>Information:</b>					
7	Assignee showing of ownership per 37 CFR 3.73(b).	17328CON5Assign1.pdf	259365	no	6
<b>Warnings:</b>					
<b>Information:</b>					
8	Assignee showing of ownership per 37 CFR 3.73(b).	17328CON5Assign2.pdf	1040327	no	25
<b>Warnings:</b>					
<b>Information:</b>					
9	Fee Worksheet (PTO-875)	fee-info.pdf	8312	no	2
<b>Warnings:</b>					
<b>Information:</b>					
<b>Total Files Size (in bytes):</b>			1742825		
<p>This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.</p> <p><b><u>New Applications Under 35 U.S.C. 111</u></b>          If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.</p> <p><b><u>National Stage of an International Application under 35 U.S.C. 371</u></b>          If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.</p>					